Cridanimod

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cridanimod（10-羧甲基-9-吖啶酮、10-CMA、XBIO-101）是一种有效的 I 型干扰素 (IFN) 诱导剂，可直接与 STING 结合并通过 TBK1/IRF3 途径引发强烈的抗病毒反应。

Cridanimod (10-carboxymethyl-9-acridanone, 10-CMA, XBIO-101) is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route; displays extraordinary activity in phosphorylating IRF3 in the murine system; also increases progesterone receptor (PrR) expression in endometrial tissue.Ovarian Cancer Phase 2 Clinical(In Vivo):Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner.

——

Animal Model:Athymic mice with hec50co cells Dosage:1, 3, 6 mg Administration:IM; twice a week Result:Had a significantly longer survival time.

10-carboxymethyl-9-acridanone | 10-CMA | XBIO-101

Immunology/Inflammation

STING

mSTING

Cancer

Ovarian Cancer

38609-97-1

253.25

C15H11NO3

>98% (HPLC)

DMSO: 25 mg/mL, 98.7 mM （ < 1 mg/ml refers to the product slightly soluble or insoluble )

C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3N2CC(=O)O

2-(9-oxoacridin-10-yl)acetic acid

(-20℃)

With Ice Pack

≥ 2 years